BC Week In Review | Jun 16, 2017
Financial News

LifeArc raises L30M across two funds

LifeArc (London, U.K.), a medical research charity formerly known as MRC Technology , established two global funds worth a combined £30 million ($38.2 million). The Philanthropic Fund will provide grants for academic research funded by other...
BC Extra | Jun 14, 2017
Financial News

LifeArc raises £30M across two funds

LifeArc (London, U.K.), a medical research charity formerly known as MRC Technology , established two global funds worth a combined £30 million ($38.2 million). The Philanthropic Fund will provide grants for academic research funded by other...
BC Innovations | Apr 20, 2017
Finance

Zuckerberg’s research network

The Chan Zuckerberg Biohub took its first concrete steps toward knitting together the Bay Area research base with the announcement of the first class of its $50 million CZ Biohub Investigators program. The idea is...
BC Week In Review | Mar 24, 2017
Company News

MRC Technology, Newsummit Biopharma deal

Medical research charity MRC granted Newsummit rights to develop an undisclosed antibody to treat HCV infection. The antibody was discovered by MRC- University of Glasgow Centre for Virus Research (Glasgow, U.K.) and humanized by MRC....
BC Innovations | Jan 18, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum ANG2 levels could help predict responses to anti- CTLA4 or anti- PD-1 mAbs in melanoma patients. In 134 melanoma patients treated with the anti-CTLA4 mAb Yervoy ipilimumab, Yervoy plus a biosimilar...
BC Innovations | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

  Formation of new PPPs cooled off considerably this summer after a blistering pace in 2Q16, with the fewest preclinical research-oriented partnerships since 3Q14. Only 37 partnerships were recorded by BioCentury in 3Q16, a nearly...
BC Innovations | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Focal adhesion kinase (FAK); programmed cell death 1 (PD-1; PDCD1; CD279)

Cancer INDICATION: Pancreatic cancer Patient sample and mouse studies suggest combining a FAK inhibitor, anti- PD-1 mAb and Gemzar gemcitabine could help treat pancreatic ductal adenocarcinoma (PDAC). In PDAC patients, levels of FAK protein and...
BC Innovations | Jul 28, 2016
Finance

MRCT looks east

MRC Technology (MRCT) is broadening its reach to Asia with a new strategy that extends beyond the source and geography of its original mission to serve as the tech transfer arm of the U.K.'s Medical...
BC Week In Review | Jul 25, 2016
Company News

MRC Technology, DRI Capital deal

MRC Technology sold a portion of its royalty rights to Keytruda pembrolizumab to DRI Capital for $150 million. The not-for-profit said it sold a “percentage of future royalties until a pre-agreed aggregate fixed cap of...
BC Extra | Jul 15, 2016
Financial News

MRC sells Keytruda royalty rights for $150M

MRC Technology (London, U.K.) sold a portion of its royalty rights to PD-1 inhibitor Keytruda pembrolizumab to DRI Capital for $150 million. Merck & Co. Inc. (NYSE:MRK) markets Keytruda to treat melanoma and non-small cell...
Items per page:
1 - 10 of 62
BC Week In Review | Jun 16, 2017
Financial News

LifeArc raises L30M across two funds

LifeArc (London, U.K.), a medical research charity formerly known as MRC Technology , established two global funds worth a combined £30 million ($38.2 million). The Philanthropic Fund will provide grants for academic research funded by other...
BC Extra | Jun 14, 2017
Financial News

LifeArc raises £30M across two funds

LifeArc (London, U.K.), a medical research charity formerly known as MRC Technology , established two global funds worth a combined £30 million ($38.2 million). The Philanthropic Fund will provide grants for academic research funded by other...
BC Innovations | Apr 20, 2017
Finance

Zuckerberg’s research network

The Chan Zuckerberg Biohub took its first concrete steps toward knitting together the Bay Area research base with the announcement of the first class of its $50 million CZ Biohub Investigators program. The idea is...
BC Week In Review | Mar 24, 2017
Company News

MRC Technology, Newsummit Biopharma deal

Medical research charity MRC granted Newsummit rights to develop an undisclosed antibody to treat HCV infection. The antibody was discovered by MRC- University of Glasgow Centre for Virus Research (Glasgow, U.K.) and humanized by MRC....
BC Innovations | Jan 18, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum ANG2 levels could help predict responses to anti- CTLA4 or anti- PD-1 mAbs in melanoma patients. In 134 melanoma patients treated with the anti-CTLA4 mAb Yervoy ipilimumab, Yervoy plus a biosimilar...
BC Innovations | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

  Formation of new PPPs cooled off considerably this summer after a blistering pace in 2Q16, with the fewest preclinical research-oriented partnerships since 3Q14. Only 37 partnerships were recorded by BioCentury in 3Q16, a nearly...
BC Innovations | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Focal adhesion kinase (FAK); programmed cell death 1 (PD-1; PDCD1; CD279)

Cancer INDICATION: Pancreatic cancer Patient sample and mouse studies suggest combining a FAK inhibitor, anti- PD-1 mAb and Gemzar gemcitabine could help treat pancreatic ductal adenocarcinoma (PDAC). In PDAC patients, levels of FAK protein and...
BC Innovations | Jul 28, 2016
Finance

MRCT looks east

MRC Technology (MRCT) is broadening its reach to Asia with a new strategy that extends beyond the source and geography of its original mission to serve as the tech transfer arm of the U.K.'s Medical...
BC Week In Review | Jul 25, 2016
Company News

MRC Technology, DRI Capital deal

MRC Technology sold a portion of its royalty rights to Keytruda pembrolizumab to DRI Capital for $150 million. The not-for-profit said it sold a “percentage of future royalties until a pre-agreed aggregate fixed cap of...
BC Extra | Jul 15, 2016
Financial News

MRC sells Keytruda royalty rights for $150M

MRC Technology (London, U.K.) sold a portion of its royalty rights to PD-1 inhibitor Keytruda pembrolizumab to DRI Capital for $150 million. Merck & Co. Inc. (NYSE:MRK) markets Keytruda to treat melanoma and non-small cell...
Items per page:
1 - 10 of 62